Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05598957
Other study ID # 2022/10/17
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 1, 2022
Est. completion date February 1, 2023

Study information

Verified date March 2023
Source Marmara University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

There were many studies in the literature discussing the effects of vitamin D deficiency and the role of vitamin D supplementation in SARS-CoV-2 patients. Combined with the possible impact of vitamin D on the pathogenesis of SARS-CoV-2 infection, it is concluded that VDBP-regulated bioavailable and free vitamin D concentrations modulate the human immune system response to viral infections. Because of the gap in the literature, it was emphasized that studies should focus on vitamin D binding protein (VDBP) and gene polymorphism. In this study, it was aimed to investigate the relationship between SARS-CoV-2 infection severity and free and bioavailable vitamin D levels.


Description:

It was aimed to investigate the relationship between SARS-CoV-2 infection severity and free and bioavailable vitamin D levels. This study was planned as a case-control study with patients hospitalized in the Haseki Training and Research Hospital Pediatric Infection Service. A total of 82 children, including at least 20 patients in each group were included in the study. The study group was divided into three groups according to COVID-19 WHO clinical progression Scale: unaffected (Group 1), mild (Group 2) and moderate (group 3). In order to investigate the relationship between disease severity and free and bioavailable vitamin D; 25OH vitamin d (μg/L), albumin (g/l) and VDBP levels (ELISA) were used. Vitamin D metabolites were calculated by using Bikle and Vermeulen methods (free Vitamin D BIKLE, free vitamin DVERMEULEN, bioavailable vitamin D). And these three vitamin D parameter levels were compared between groups.


Recruitment information / eligibility

Status Completed
Enrollment 82
Est. completion date February 1, 2023
Est. primary completion date December 1, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 1 Year to 18 Years
Eligibility Inclusion Criteria: - Age between 1-18 years old, - Positive for SARS-CoV-2 PCR or positive for IgM in the SARS-CoV-2 antibody test (card test or ELISA), - Do not have a chronic disease (cystic fibrosis, etc.), - Volunteer to participate in the study. Exclusion Criteria: - Being < 1 year of age

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Vitamin D Binding protein
Vitamin D-free and bioavailable metabolites were calculated by using Bikle and Vermeulen methods with using albumin, 25-OH vitamin D, vitamin D binding protein (ELISA kit) levels

Locations

Country Name City State
Turkey Haseki Training and Research Hospital Istanbul

Sponsors (1)

Lead Sponsor Collaborator
Marmara University

Country where clinical trial is conducted

Turkey, 

References & Publications (3)

Charoenngam N, Shirvani A, Reddy N, Vodopivec DM, Apovian CM, Holick MF. Authors' Reply: Vitamin D Sufficiency and COVID-19: Is Vitamin D Binding Protein (and Its Polymorphism) the Missing Link? Endocr Pract. 2021 Jun;27(6):646-647. doi: 10.1016/j.eprac.2021.03.016. Epub 2021 Apr 2. No abstract available. — View Citation

Speeckaert MM, Delanghe JR. Vitamin D binding protein and its polymorphisms may explain the link between vitamin D deficiency and COVID-19. Sci Prog. 2021 Oct;104(4):368504211053510. doi: 10.1177/00368504211053510. No abstract available. — View Citation

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):106 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The relationship between free vitamin D levels and SARS CoV-2 infection severity. The differences between free vitamin D levels in SARS CoV-2 infected patients according to the symptom severity. SARS CoV-2 infection severity will be categorized according to COVID19 WHO clinical progression Scale as uninfected, mild, moderate to severe. baseline (at the time of diagnosis)
Primary The relationship between bioavailable vitamin D levels and SARS CoV-2 infection severity. The differences between bioavailable vitamin D levels in SARS CoV-2 infected patients according to the symptom severity. SARS CoV-2 infection severity will be categorized according to COVID19 WHO clinical progression Scale as uninfected, mild, moderate to severe. baseline (at the time of diagnosis)
See also
  Status Clinical Trial Phase
Recruiting NCT05036941 - A Trial of Two Mask Systems in Preventing SARS CoV-2 in Healthcare Workers (HCW) N/A
Terminated NCT04748783 - Antiviral Efficacy and Acceptability of Mouth Rinses for Inactivation of COVID-19 Phase 2
Completed NCT04319731 - A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure Early Phase 1
Recruiting NCT05587868 - COVID-19 Vaccination Status and The Clinical Outcomes of Long COVID-19 Patients
Active, not recruiting NCT04756466 - Effect of the Consumption of a Lactobacillus Strain on the Incidence of Covid-19 in the Elderly N/A